MacroGenics Files 8-K on Shareholder Vote Matters

Ticker: MGNX · Form: 8-K · Filed: 2024-05-23T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, shareholder-vote, sec-filing

Related Tickers: MGNX

TL;DR

MGNX filed an 8-K for a shareholder vote - big stuff coming.

AI Summary

On May 21, 2024, MacroGenics, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The company, incorporated in Delaware with its principal executive offices in Rockville, Maryland, is involved in the pharmaceutical preparations industry. This filing indicates a significant corporate event requiring shareholder approval.

Why It Matters

This filing signals a material event requiring shareholder approval, which could impact the company's strategic direction or financial structure.

Risk Assessment

Risk Level: medium — Filings related to shareholder votes often precede significant corporate actions that can carry inherent risks and uncertainties.

Key Numbers

Key Players & Entities

FAQ

What specific matters are being submitted for a vote of security holders?

The filing indicates a 'Submission of Matters to a Vote of Security Holders' but does not specify the exact matters within the provided text.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on May 21, 2024.

What is MacroGenics, Inc.'s principal executive office address?

The principal executive offices are located at 9704 Medical Center Drive, Rockville, Maryland 20850.

On which exchange is MacroGenics, Inc. common stock traded?

MacroGenics, Inc. common stock is traded on the Nasdaq Global Select Market.

What is the trading symbol for MacroGenics, Inc. common stock?

The trading symbol for MacroGenics, Inc. common stock is MGNX.

Filing Stats: 679 words · 3 min read · ~2 pages · Grade level 10.5 · Accepted 2024-05-23 16:24:18

Key Financial Figures

Filing Documents

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. MacroGenics, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders on May 21, 2024. A total of 55,633,111 shares of the Company's common stock were present or represented by proxy at the meeting, which represented approximately 89% of the Company's 62,560,502 shares of common stock that were outstanding and entitled to vote at the meeting as of the record date of March 22, 2024. Stockholders considered the four proposals outlined below, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 8, 2024 (the "Proxy Statement"). Proposal 1 . The election of three nominees to serve as Class II directors, each for a term of three years. All director nominees were elected. The voting results were as follows: Nominees For Withheld Broker Non-Votes Scott Jackson 45,427,543 6,045,759 4,159,809 Margaret A. Liu, M.D. 49,514,571 2,253,648 3,864,892 David Stump, M.D. 46,614,076 5,136,726 3,882,309 Proposal 2 . The ratification of the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for fiscal year 2024. Proposal 2 was approved. The voting results were as follows: For Against Abstain Broker Non-Votes 53,484,470 2,134,398 14,243 — Proposal 3 . To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's Proxy Statement. Stockholders approved the compensation of the Company's named executive officers. The voting results were as follows: For Against Abstain Broker Non-Votes 49,530,270 2,225,779 12,170 3,864,892 Proposal 4 . To approve an amendment to the MacroGenics, Inc. 2023 Equity Incentive Plan (the "2023 Plan") to increase the number of shares of our common stock available for issuance thereunder by 2,000,000 shares. Stockholders approved the a

View on Read The Filing